As a first step, Enorama Pharma has chosen to investigate the possibilities to develop a medicated gum for treatment of allergic rhinitis, a market with huge potential. An initial technical evaluation has been performed regarding some active substances. The analysis points out seven APIs as potential candidates. Enorama Pharma is currently searching for partners within allergic rhinits.
Cough & Cold
Enorama Pharma entered into an agreement with the company MediiGum LLC to conduct a screening study of active substances in the Cough & Cold therapy area. The preliminary study investigated the suitability of active substances for chewing gum administration. MediiGum LLC (Florida, USA) is a newly formed company with plans to launch a number of medical chewing gum formulations in the future. The cost of this initial analysis was covered by MediiGum LLC.
The screening study was completed in June 2019 and an evaluation of the study results has been initiated with the client.